Chinese Journal of Dermatology ›› 2019, Vol. 52 ›› Issue (5): 337-339.doi: 10.3760/cma.j.issn.0412-4030.2019.05.012

Previous Articles     Next Articles

Efficacy of desloratadine citrate disodium in the treatment of chronic urticaria and its effect on serum interleukin-23, interleukin-33 and PARC/CCL-18

Xu Yanfeng1, Du Weiping2, Luo Zhicheng3, Shen Hailian1   

  1. 1Department of Dermatology, Wuwei Oncology Hospital, Wuwei 733000, Gansu, China; 2Department of Dermatology, Wuwei People′s Hospital, Wuwei 733000, Gansu, China; 3Department of Dermatology, Lanzhou University Second Hospital, Lanzhou 730030, China
  • Received:2018-10-29 Revised:2019-03-27 Online:2019-05-15 Published:2019-04-30
  • Contact: Xu Yanfeng
  • Supported by:
    Wuwei Science and Technology Planning Project of Gansu Province (WW170216)

Abstract: 【Abstract】 Objective To compare the efficacy of desloratadine citrate disodium versus loratadine in the treatment of chronic urticaria (CU), and to evaluate their effect on serum interleukin (IL)-23, IL-33 and pulmonary and activation-regulated chemokine/CC chemokine ligand 18 (PARC/CCL-18). Methods From January 2013 to December 2016, 120 CU patients treated in Department of Dermatology, Wuwei Oncology Hospital were enrolled into this study, and divided into study group and control group by using a random number table. Patients in the study group took oral desloratadine citrate disodium tablets 8.8 mg once a day, and patients in the control group took loratadine tablets 10 mg once a day. The treatment lasted 28 days. The therapeutic effect was compared between the two groups, and changes in serum levels of IL-23, IL-33 and PARC/CCL-18 were compared before and after treatment. Statistical analysis was carried out by using two-sample t test and chi-square test for comparing indices between the two groups. Results The response rate was significantly higher in the study group (88.33%, 53/60) than in the control group ([61.67%, 37/60], χ2 = 15.352, P < 0.01). After the treatment, the serum levels of IL-23, IL-33 and PARC/CCL-18 in the study group significantly decreased to (87.72 ± 22.16) ng/L, (95.94 ± 18.27) ng/L, (85.93 ± 27.34) μg/L respectively, which were all lower than those in the control group ([104.21 ± 32.05] ng/L, [106.27 ± 20.93]ng/L, [95.72 ± 30.28] μg/L, respectively; t = 3.264, ?4.034, 3.934 respectively, P = 0.020, 0.006, 0.015 respectively). No significant difference was observed in the incidence of adverse reactions between the study group and control group (P = 0.298). Conclusion Desloratadine citrate disodium can markedly improve the clinical symptoms of CU with favorable safety, likely by inhibiting the immune response of the body and reducing the effect of chemokines on the chemotaxis of inflammatory cells.

Key words: Loratadine, Urticaria, Interleukin?23, Interleukin?33, Desloratadine citrate disodium, PARC/CCL-18